Association between BRAF V600E mutation and recurrence of papillary thyroid cancer Journal Article
| Authors: | Xing, M.; Alzahrani, A. S.; Carson, K. A.; Shong, Y. K.; Kim, T. Y.; Viola, D.; Elisei, R.; Bendlová, B.; Yip, L.; Mian, C.; Vianello, F.; Tuttle, R. M.; Robenshtok, E.; Fagin, J. A.; Puxeddu, E.; Fugazzola, L.; Czarniecka, A.; Jarzab, B.; O'Neill, C. J.; Sywak, M. S.; Lam, A. K.; Riesco-Eizaguirre, G.; Santisteban, P.; Nakayama, H.; Clifton-Bligh, R.; Tallini, G.; Holt, E. H.; Sýkorová, V. |
| Article Title: | Association between BRAF V600E mutation and recurrence of papillary thyroid cancer |
| Abstract: | Purpose: To investigate the prognostic value of BRAFV600E mutation for the recurrence of papillary thyroid cancer (PTC) Patients and Methods: This was a retrospective multicenter study of the relationship between BRAF V600E mutation and recurrence of PTC in 2,099 patients (1,615 women and 484 men), with a median age of 45 years (interquartile range [IQR], 34 to 58 years) and a median follow-up time of 36 months (IQR, 14 to 75 months) Results: The overall BRAF V600E mutation prevalence was 48.5% (1,017 of 2,099). PTC recurrence occurred in 20.9% (213 of 1,017) of BRAFV600E mutation-positive and 11.6% (125 of 1,082) of BRAFV600E mutation-negative patients. Recurrence rates were 47.71 (95% CI, 41.72 to 54.57) versus 26.03 (95% CI, 21.85 to 31.02) per 1,000 person-years in BRAF mutation-positive versus - Negative patients (P <.001), with a hazard ratio (HR) of 1.82 (95% CI, 1.46 to 2.28), which remained significant in a multivariable model adjusting for patient sex and age at diagnosis, medical center, and various conventional pathologic factors. Significant association between BRAF mutation and PTC recurrence was also found in patients with conventionally low-risk disease stage or II and micro-PTC and within various subtypes of PTC. For example, in BRAF mutation-positive versus - Negative follicular-variant PTC, recurrence occurred in 21.3% (19 of 89) and 7.0% (24 of 342) of patients, respectively, with recurrence rates of 53.84 (95% CI, 34.34 to 84.40) versus 19.47 (95% CI, 13.05 to 29.04) per 1,000 person-years (P <.001) and an HR of 3.20 (95% CI, 1.46 to 7.02) after adjustment for clinicopathologic factors. BRAF mutation was associated with poorer recurrence-free probability in Kaplan-Meier survival analyses in various clinicopathologic categories. Conclusion: This large multicenter study demonstrates an independent prognostic value of BRAF V600E mutation for PTC recurrence in various clinicopathologic categories. |
| Keywords: | adult; gene mutation; major clinical study; cancer recurrence; cancer risk; cancer staging; recurrence risk; genetic association; retrospective study; multicenter study; thyroid cancer; hazard ratio; kaplan meier method; genetic risk; b raf kinase; papillary thyroid cancer; low risk patient; cancer prognosis; human; male; female; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 1 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-01-01 |
| Start Page: | 42 |
| End Page: | 50 |
| Language: | English |
| DOI: | 10.1200/jco.2014.56.8253 |
| PROVIDER: | scopus |
| PMCID: | PMC4268252 |
| PUBMED: | 25332244 |
| DOI/URL: | |
| Notes: | Export Date: 2 February 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work